Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025

Outcomes and Adverse Events of WHO Shorter Regimen in the Treatment of Multi-Drug Resistant Tuberculosis in Bhutan: A Longitudinal Study.

View Full Paper
Ask AI
Bookmark
Share

Authors

GNGaki NimaTDThinley DorjiCDChencho Dorji

Discussion

Loading...

Member takes

Overview

Longitudinal analysis shows 94% success in MDR-TB treatment in Bhutan, indicating effective outcomes and monitoring of adverse events.

Key Points

  • The treatment success rate for MDR-TB was high at 94%, and achieving sputum and culture conversion was significant.
  • By the end of four months, 40 patients (86%) achieved sputum smear conversion, indicating effective treatment.
  • Patients experienced various adverse events, including nausea and QTc prolongation, necessitating close monitoring.
  • The study involved 52 patients treated with the WHO shorter regimen from 2018 to 2020, highlighting its practical implications.

Cite This Study

Nima et al. (2025) studied this question.

synapsesocial.com/papers/68d4205e713b0b5dfea69517https://doi.org/10.1002/hsr2.71241
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparing the longer regimen and the shorter regimen for multidrug-resistant pulmonary tuberculosis patients treated under the programmatic management of drug-resistant tuberculosis2025
  2. 2Treatment Outcome of Bedaquiline-Based Oral Regimens for Drug-Resistant Tuberculosis in a High-Burden Setting.2025
  3. 3Evaluating Treatment Outcomes in Special Populations with Multidrug- and Extensively Drug-Resistant Tuberculosis: A Comparative Cohort Study2025
  4. 4Adverse drug reactions to the nine-month all-oral and 18-month regimens for multidrug-resistant tuberculosis in Indonesia2025
  5. 5P37 The effectiveness of a new short regimen for drug-sensitive TB: preliminary results2025